PVI
ADMS

Pura Vida Investments’s Adamas Pharmaceuticals ADMS Stock Holding History

Pura Vida Investments’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-200,000
Closed -$4.23M – 105
2017
Q3 		$4.23M Buy
+200,000
New +$3.67M 1.24% 32

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pura Vida Investments's ADMS Position: Q3 2017 in Review

Pura Vida Investments sold out of Adamas Pharmaceuticals (ADMS) in Q3 2017, closing a stake of 79,103 shares — an estimated $1.45M sold.

Pura Vida Investments first reported a position in ADMS in Q1 2017 and held it in 2 quarters. The position peaked at $4.16M in Q1 2017. 95 funds tracked by Wall St. Rank hold ADMS as of Q3 2017.

  • Pura Vida Investments reported no remaining Adamas Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Pura Vida Investments sold 79,103 Adamas Pharmaceuticals shares in Q3 2017, an estimated $1.45M.
  • Pura Vida Investments first reported a position in Adamas Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Pura Vida Investments's Adamas Pharmaceuticals position peaked at $4.16M in Q1 2017.
  • 95 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2017.

Based on Pura Vida Investments's 13F filing for Q3 2017, filed 14 Nov 2017.